Publications
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
Avezum A,Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, *Pais P*, Erol C, Diaz R, Bahit MC, Bartunek J, Caterina RD, Goto S, Ruzyllo W, Zhu J, Granger CB & Alexander JH. Background
Apixaban is approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial included a substantial number of patients with valvular heart disease and only excluded patients with clinically significant mitral stenosis or mechanical prosthetic heart valves.
